Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Lung Cancer Liquid Biopsy Market 2020-2024

Published by TechNavio (Infiniti Research Ltd.) Product code 973408
Published Content info 120 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Lung Cancer Liquid Biopsy Market 2020-2024
Published: October 26, 2020 Content info: 120 Pages
Description

Technavio has been monitoring the lung cancer liquid biopsy market and it is poised to grow by $ 292.89 mn during 2020-2024, progressing at a CAGR of 16% during the forecast period. Our reports on the lung cancer liquid biopsy market provide a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven rising incidence of lung cancer, increasing participation in conferences to endorse the products and technologically advanced products. In addition, the rising incidence of lung cancer is anticipated to boost the growth of the market as well.

The lung cancer liquid biopsy market analysis includes product segment and geographical landscapes.

Technavio's lung cancer liquid biopsy market is segmented as below:

By Product

  • CTCs and ctDNA
  • Exosomes and RNA

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing partnership agreements as one of the prime reasons driving the lung cancer liquid biopsy market growth during the next few years. Also, vendors' focus on clinical trials and application of liquid biopsy for personalized treatment will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our lung cancer liquid biopsy market report covers the following areas:

  • Lung cancer liquid biopsy market sizing
  • Lung cancer liquid biopsy market forecast
  • Lung cancer liquid biopsy market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading lung cancer liquid biopsy market vendors that include Biocartis Group NV, Biocept Inc., Bio-Rad Laboratories Inc., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., Illumina Inc., QIAGEN NV, Sysmex Corp., Thermo Fisher Scientific Inc., and Trovagene Inc. Also, the lung cancer liquid biopsy market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents
Product Code: IRTNTR45510

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • CTCs and ctDNA - Market size and forecast 2019-2024
  • Exosomes and RNA - Market size and forecast 2019-2024
  • Market opportunity by Product

Market Segmentation by End-user

  • Market segments
  • Comparison by End-user
  • Clinical diagnostic laboratories - Market size and forecast 2019-2024
  • Hospitals and clinics - Market size and forecast 2019-2024
  • Physicians' office laboratories - Market size and forecast 2019-2024
  • Market opportunity by End-user

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume drivers - Demand led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Biocartis Group NV
  • Biocept Inc.
  • Bio-Rad Laboratories Inc.
  • Bio-Techne Corp.
  • F. Hoffmann-La Roche Ltd.
  • Illumina Inc.
  • QIAGEN NV
  • Sysmex Corp.
  • Thermo Fisher Scientific Inc.
  • Trovagene Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Key Finding 9
  • 9: Parent market
  • 10: Market characteristics
  • 11: Offerings of vendors included in the market definition
  • 12: Market segments
  • 13: Global - Market size and forecast 2019 - 2024 ($ million)
  • 14: Global market: Year-over-year growth 2019 - 2024 (%)
  • 15: Five forces analysis 2019 & 2024
  • 16: Bargaining power of buyers
  • 17: Bargaining power of suppliers
  • 18: Threat of new entrants
  • 19: Threat of substitutes
  • 20: Threat of rivalry
  • 21: Market condition - Five forces 2019
  • 22: Product - Market share 2019-2024 (%)
  • 23: Comparison by Product
  • 24: CTCs and ctDNA - Market size and forecast 2019-2024 ($ million)
  • 25: CTCs and ctDNA - Year-over-year growth 2019-2024 (%)
  • 26: Exosomes and RNA - Market size and forecast 2019-2024 ($ million)
  • 27: Exosomes and RNA - Year-over-year growth 2019-2024 (%)
  • 28: Market opportunity by Product
  • 29: End user - Market share 2019-2024 (%)
  • 30: Comparison by End user
  • 31: Clinical diagnostic laboratories - Market size and forecast 2019-2024 ($ million)
  • 32: Clinical diagnostic laboratories - Year-over-year growth 2019-2024 (%)
  • 33: Hospitals and clinics - Market size and forecast 2019-2024 ($ million)
  • 34: Hospitals and clinics - Year-over-year growth 2019-2024 (%)
  • 35: Market opportunity by End user
  • 36: Customer landscape
  • 37: Market share by geography 2019-2024 (%)
  • 38: Geographic comparison
  • 39: North America - Market size and forecast 2019-2024 ($ million)
  • 40: North America - Year-over-year growth 2019-2024 (%)
  • 41: Europe - Market size and forecast 2019-2024 ($ million)
  • 42: Europe - Year-over-year growth 2019-2024 (%)
  • 43: Asia - Market size and forecast 2019-2024 ($ million)
  • 44: Asia - Year-over-year growth 2019-2024 (%)
  • 45: ROW - Market size and forecast 2019-2024 ($ million)
  • 46: ROW - Year-over-year growth 2019-2024 (%)
  • 47: Key leading countries
  • 48: Market opportunity by geography ($ million)
  • 49: Impact of drivers and challenges
  • 50: Vendor landscape
  • 51: Landscape disruption
  • 52: Industry risks
  • 53: Vendors covered
  • 54: Market positioning of vendors
  • 55: Biocartis Group NV - Overview
  • 56: Biocartis Group NV - Product and service
  • 57: Biocartis Group NV - Key offerings
  • 58: Biocartis Group NV - Key customers
  • 59: Biocartis Group NV - Segment focus
  • 60: Biocept Inc. - Overview
  • 61: Biocept Inc. - Business segments
  • 62: Biocept Inc. - Key offerings
  • 63: Biocept Inc. - Key customers
  • 64: Biocept Inc. - Segment focus
  • 65: Bio-Rad Laboratories Inc. - Overview
  • 66: Bio-Rad Laboratories Inc. - Business segments
  • 67: Bio-Rad Laboratories Inc. - Key offerings
  • 68: Bio-Rad Laboratories Inc. - Key customers
  • 69: Bio-Rad Laboratories Inc. - Segment focus
  • 70: Bio-Techne Corp. - Overview
  • 71: Bio-Techne Corp. - Business segments
  • 72: Bio-Techne Corp. - Key offerings
  • 73: Bio-Techne Corp. - Key customers
  • 74: Bio-Techne Corp. - Segment focus
  • 75: F. Hoffmann-La Roche Ltd. - Overview
  • 76: F. Hoffmann-La Roche Ltd. - Business segments
  • 77: F. Hoffmann-La Roche Ltd. - Key offerings
  • 78: F. Hoffmann-La Roche Ltd. - Key customers
  • 79: F. Hoffmann-La Roche Ltd. - Segment focus
  • 80: Illumina Inc. - Overview
  • 81: Illumina Inc. - Product and service
  • 82: Illumina Inc. - Key offerings
  • 83: Illumina Inc. - Key customers
  • 84: Illumina Inc. - Segment focus
  • 85: QIAGEN NV - Overview
  • 86: QIAGEN NV - Business segments
  • 87: QIAGEN NV - Key offerings
  • 88: QIAGEN NV - Key customers
  • 89: QIAGEN NV - Segment focus
  • 90: Sysmex Corp. - Overview
  • 91: Sysmex Corp. - Business segments
  • 92: Sysmex Corp. - Key offerings
  • 93: Sysmex Corp. - Key customers
  • 94: Sysmex Corp. - Segment focus
  • 95: Thermo Fisher Scientific Inc. - Overview
  • 96: Thermo Fisher Scientific Inc. - Business segments
  • 97: Thermo Fisher Scientific Inc. - Key offerings
  • 98: Thermo Fisher Scientific Inc. - Key customers
  • 99: Thermo Fisher Scientific Inc. - Segment focus
  • 100: Trovagene Inc. - Overview
  • 101: Trovagene Inc. - Product and service
  • 102: Trovagene Inc. - Key offerings
  • 103: Trovagene Inc. - Key customers
  • 104: Trovagene Inc. - Segment focus
  • 105: Currency conversion rates for US$
  • 106: Research Methodology
  • 107: Validation techniques employed for market sizing
  • 108: Information sources
  • 109: List of abbreviations
Back to Top